

# Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 566 • December 2015

## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Jamp Pharma Corporation that the shortage of Jamp-Tobramycin 40 mg/ml Injection (DIN 02420287) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective January 14, 2016**.

### TOBRAMYCIN SULFATE

#### 40 MG / ML (BASE) INJECTION

00002420287	JAMP-TOBRAMYCIN	JPC	\$ 2.7250
00002382814	TOBRAMYCIN USP	MYP	\$ 2.7250
00002241210	TOBRAMYCIN	SDZ	\$ 3.7070

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Cilazapril 5 mg Tablet (DIN 02280469) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective January 14, 2016**.

### CILAZAPRIL

#### 5 MG ORAL TABLET

00002291150	APO-CILAZAPRIL	APX	\$ 0.2085
00002350998	CILAZAPRIL	SNS	\$ 0.2085
00002283794	MYLAN-CILAZAPRIL	MYP	\$ 0.2085
00002266377	NOVO-CILAZAPRIL	TEV	\$ 0.2085
00002280469	PMS-CILAZAPRIL	PMS	\$ 0.2085
00001911481	INHIBACE	HLR	\$ 0.9071

Alberta Blue Cross has been advised by AA Pharma Inc. that the shortage of Ketorolac 0.5% Ophthalmic Solution (DIN 02245821) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping **effective January 15, 2016**.

### KETOROLAC TROMETHAMINE

#### 0.5 % OPHTHALMIC SOLUTION

00002245821	KETOROLAC	AAP	\$ 2.5960
00001968300	ACULAR	ALL	\$ 3.4100

continued on next page ...

... continued from previous page

## Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) manufactured by Pharmaceutical Partners of Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of December 10, 2015, all claims for of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

---

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)  
**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

---



\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.566 2015/12